Tag Archives: Global

Anti-Restenotic Drug Delivery with the AGENT Drug-Coated Balloon: Interview with Dr. Ian Meredith, Global CMO, Boston Scientific

Boston Scientific recently announced a clinical trial of its AGENT drug coated balloon. The device is coated with paclitaxel, an anti-restenotic drug, and aims to deliver the medication to the affected vessel wall during a percutaneous procedure. Coronary in-stent restenosis (ISR) is caused by occlusive scar tissue that develops in the stented portion of a… Read More »

Worldwide spectrum experts drive spectrum sharing success at DSA Global Summit 2021

Data reveals the growing need for spectrum access for broadband, Wi-Fi and 5G networks and regulators give updates on spectrum sharing priorities. Washington D.C., USA, 10 June 2021 – Sessions over the first two days of the Dynamic Spectrum Alliance’s (DSA’s) Global Summit have highlighted the spectrum sharing lessons being learnt between countries worldwide and… Read More »

Covid-19 news: Pandemic should drive global health reform, says report

By Michael Le Page , Clare Wilson , Jessica Hamzelou , Sam Wong , Graham Lawton , Adam Vaughan , Conrad Quilty-Harper and Layal Liverpool Medical workers in overalls stretch a patient under intensive care into the newly built Columbus Covid 2 temporary hospital to fight the new coronavirus infection. ANDREAS SOLARO/AFP via Getty Images… Read More »

Chiesi Global Rare Diseases Announces FDA Approval of Ferriprox (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease

May 1, 2021 Approval is based on demonstrated reduction in liver iron concentration Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia – BOSTON, May 1, 2021 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today… Read More »